The death of cost-minimization analysis?
Four different types of evaluation methods, cost-benefit analysis (CBA), cost-utility analysis (CUA), cost-effectiveness analysis (CEA) and cost-minimization analysis (CMA), are usually distinguished. In this note, we pronounce the (near) death of CMA by showing the rare circumstances under which CMA is an appropriate method of analysis. We argue that it is inappropriate for separate and sequential hypothesis tests on differences in effects and costs to determine whether incremental cost-effectiveness (or cost-utility) should be estimated. We further argue that the analytic focus should be on the estimation of the joint density of cost and effect differences, the quantification of uncertainty surrounding the incremental cost-effectiveness ratio and the presentation of such data as cost-effectiveness acceptability curves. Two examples from recently published CEA are employed to illustrate the issues. The first shows a situation where analysts might be tempted (inappropriately) to employ CMA rather than CEA. The second illustrates one of the rare circumstances in which CMA may be justified as a legitimate form of analysis.
Briggs
A H
AH
Health Economics Research Centre, University of Oxford, UK. andrew.briggs@ihs.ox.ac.uk
O'Brien
B J
BJ
D000925:Anticoagulants / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000379:methods*; D017147:Defibrillators, Implantable / Q000191:economics; D005102:Health Expenditures / Q000706:statistics & numerical data; D006302:Health Services Research / Q000379:methods*; D006801:Humans; D014481:United States; D020246:Venous Thrombosis / Q000188:drug therapy / Q000191:economics
D000925:Anticoagulants